Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 10,623 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • San Diego, California + 15 more

Conditions: Carcinoma, Hepatocellular
Interventions: MTC-DOX for Injection; Drug
Lead sponsor: FeRx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 11
States / cities: Long Beach, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions: HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US); Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 16 Years to 69 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Phenylketonurias
Interventions: sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: Los Angeles, California • Oakland, California • New Haven, Connecticut + 10 more

Conditions: Plaque Psoriasis
Interventions: Tapinarof, Vehicle Cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 40 more

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL, CLL, CLL Progression
Interventions: Rocbrutinib, Pirtobrutinib; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Skokie, Illinois • Bethesda, Maryland • Las Vegas, Nevada + 3 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Eteplirsen, Golodirsen, Casimersen; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: Opioid-use Disorder
Interventions: Interview, Surveys; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adult Solid Neoplasm
Interventions: Belinostat, Isotretinoin, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 2 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 955
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more

Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions: Nadofaragene Firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 55
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Neurotrophic Keratitis
Interventions: rhNGF 20µg/ml, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Loma Linda, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Depression, Anxiety, Adolescent Behavior, Suicidal Ideation
Interventions: IPR + GMI; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 10 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kittanning, Pennsylvania

Conditions: Migraine
Interventions: Migraine Prophylactic Therapy Only, Discontinuation of Overused Medication; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 29
States / cities: Flagstaff, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 21 more

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) sustained release tablets, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Fabry Disease
Interventions: Venglustat (GZ402671), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort); Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 80
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions: Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery; Other · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: Tislelizumab, Ociperlimab, Pembrolizumab, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more

Conditions: Acute Leukemia, Chronic Leukemia, Myelodysplasia
Interventions: biologic sample preservation procedure; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 142
States / cities: Mountain View, California • Pismo Beach, California • San Diego, California + 98 more

Conditions: COVID-19
Interventions: Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Pasritamig, Docetaxel, Prednisone/Prednisolone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 65
States / cities: Chandler, Arizona • Little Rock, Arkansas • Springdale, Arkansas + 57 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Armon Ayura (Kinova), JAECO Wrex; Device
Lead sponsor: Roxanna Marie Bendixen; Other
Eligibility: 14 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Obstetric Pain Management for Women With Opioid Use Disorder (QUEST)

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Bridging the Gap to Improve Mental Health Treatment Utilization

The MOTS (Medication Overuse Treatment Strategy) Trial

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Use of Dynamic Arm Supports to Promote Activities of Daily Living in Individuals With DMD